0001689375-22-000030.txt : 20220923
0001689375-22-000030.hdr.sgml : 20220923
20220923165742
ACCESSION NUMBER: 0001689375-22-000030
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220921
FILED AS OF DATE: 20220923
DATE AS OF CHANGE: 20220923
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KREHER NERISSA
CENTRAL INDEX KEY: 0001741850
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40969
FILM NUMBER: 221262863
MAIL ADDRESS:
STREET 1: C/O AVROBIO, INC.
STREET 2: ONE KENDALL SQ., BLDG. 300, STE. 201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entrada Therapeutics, Inc.
CENTRAL INDEX KEY: 0001689375
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813983399
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6 TIDE STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-305-1825
MAIL ADDRESS:
STREET 1: 6 TIDE STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: CycloPorters, Inc.
DATE OF NAME CHANGE: 20161104
4
1
wf-form4_166396664564604.xml
FORM 4
X0306
4
2022-09-21
0
0001689375
Entrada Therapeutics, Inc.
TRDA
0001741850
KREHER NERISSA
C/O ENTRADA THERAPEUTICS, INC.
6 TIDE STREET
BOSTON
MA
02210
0
1
0
0
Chief Medical Officer
Common Stock
2022-09-21
4
M
0
3341
2.10
A
24057
D
Common Stock
2022-09-21
4
S
0
3341
15.0833
D
20716
D
Common Stock
2022-09-23
4
M
0
939
2.10
A
21655
D
Common Stock
2022-09-23
4
S
0
939
15.0871
D
20716
D
Stock Option (Right to Buy)
2.1
2022-09-21
4
M
0
3341
0
D
2030-12-01
Common Stock
3341.0
25564
D
Stock Option (Right to Buy)
2.1
2022-09-23
4
M
0
939
0
D
2030-12-01
Common Stock
939.0
24625
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
/s/ Jared Cohen, as Attorney-in-Fact
2022-09-23